CryoPort (NASDAQ:CYRX) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened

CryoPort, Inc. (NASDAQ:CYRX)’s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $12.15 and traded as high as $15.33. CryoPort shares last traded at $15.09, with a volume of 456,217 shares trading hands.

Analyst Ratings Changes

A number of research analysts have commented on CYRX shares. Wall Street Zen raised shares of CryoPort from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Weiss Ratings cut CryoPort from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday. Jefferies Financial Group set a $13.50 price target on shares of CryoPort in a report on Monday, June 8th. BTIG Research increased their price objective on CryoPort from $17.00 to $25.00 and gave the company a “buy” rating in a report on Friday, July 24th. Finally, Craig Hallum increased their target price on shares of CryoPort from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, June 3rd. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, CryoPort has an average rating of “Moderate Buy” and a consensus target price of $18.00.

CryoPort Stock Performance

The company has a market cap of $842.80 million, a PE ratio of -18.49 and a beta of 1.89. The stock’s 50-day simple moving average is $15.41 and its 200 day simple moving average is $12.20.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. The business had revenue of $48.97 million during the quarter, compared to analysts’ expectations of $48.18 million. On average, sell-side analysts predict that CryoPort, Inc. will post -0.83 EPS for the current fiscal year.

Insider Activity at CryoPort

In other news, Director Ramkumar Mandalam sold 23,214 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $15.44, for a total value of $358,424.16. Following the completion of the transaction, the director owned 67,894 shares in the company, valued at $1,048,283.36. This trade represents a 25.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Jerrell Shelton sold 28,800 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $14.91, for a total transaction of $429,408.00. Following the transaction, the chief executive officer owned 1,201,814 shares of the company’s stock, valued at $17,919,046.74. This trade represents a 2.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 256,441 shares of company stock worth $4,051,923 in the last ninety days. Corporate insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On CryoPort

Several hedge funds have recently bought and sold shares of CYRX. Basepoint Wealth LLC purchased a new stake in CryoPort during the 4th quarter worth about $34,000. Tower Research Capital LLC TRC raised its position in shares of CryoPort by 300.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after buying an additional 4,375 shares during the period. Quadrature Capital Ltd purchased a new position in shares of CryoPort in the 4th quarter worth about $97,000. Corient Private Wealth LLC acquired a new position in CryoPort during the fourth quarter valued at approximately $113,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of CryoPort by 55.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,880 shares of the company’s stock valued at $113,000 after acquiring an additional 4,225 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.